5 results
To compare the efficacy of fesoterodine to placebo and tolterodine ER in subjects with overactive bladder after 12 weeks of treatment.
PrimaryTo demonstrate the non-inferior antiviral activity of switching to DTG +3TC once daily compared to continuation of TBR over 48 weeks in HIV-1 infected, ART therapy (ART)-experienced, virologically suppressed subjectsSecondary- To demonstrate…
To test whether the proportion of patients in remission during the last 6 months of follow up is higher for a T2T strategy compared to a T2S stop strategy.
Primary- To demonstrate non-inferior antiviral activity of DTG + 3TC versus DTG + TDF/FTC at 48 weeks in HIV-1-infected, ART-naïve subjectsSecondary- To demonstrate the antiviral activity of DTG + 3TC versus DTG + TDF/FTC at 24, 96 and 144 weeks- To…
The GO TEST OVERTURE study aims to demonstrate the superiority of the Treat to Target management strategy over a Treat to Avoid Symptoms approach in terms of clinical remission of gout symptoms.